Januvia (sitagliptin phosphate)
Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Diabetes Mellitus, Type 2
Last updated March 10, 2020
Status:
Concluded with an LOI
Manufacturer:
Astellas Pharma Inc.
Indication:
Non-metastatic Castration-resistant prostate cancer
Last updated February 26, 2020
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Chronic Myeloid Leukemia
Last updated February 19, 2020
Kuvan (sapropterin dihydrochloride)
Status:
Concluded with an LOI
Manufacturer:
BioMarin Pharmaceutical Inc.
Indication:
Phenylketonuria
Last updated February 13, 2020
Status:
Concluded with an LOI
Manufacturer:
Teva Canada Ltd.
Indication:
Rheumatoid arthritis, chronic lymphocytic leukemia, and non-Hodgkin's lymphoma
Last updated February 12, 2020
Status:
Concluded without agreement
Manufacturer:
Pfizer Canada ULC
Indication:
Non-Squamous Non-Small Cell Lung Cancer
Last updated February 11, 2020
Status:
Negotiations were not pursued
Manufacturer:
Knight Therapeutics Inc.
Indication:
Hormone Receptor-Positive Breast Cancer
Last updated February 4, 2020
Emerade (epinephrine bitartrate)
Status:
Concluded with an LOI
Manufacturer:
Bausch Health, Canada Inc.
Indication:
For the emergency treatment of severe acute allergic reactions (anaphylaxis).
Last updated February 4, 2020
Status:
Concluded with an LOI
Manufacturer:
BioMarin Pharmaceutical Inc.
Indication:
Neuronal Ceroid Lipofuscinosis Type 2
Last updated January 22, 2020
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
Peripheral T-cell Lymphoma (PTCL)
Last updated January 10, 2020